Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies

Parkinsonism and Related Disorders

Volumn 18, Issue 3, 2012, Pages 225-229

  Papathanasiou, Nikolaos D ^a   Boutsiadis, Anastasios ^b   Dickson, John ^a   Bomanji, Jamshed B ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

123I FP CIT; DaTSCAN; Dopamine transporter; Lewy body dementia; Meta analysis

Indexed keywords

IOFLUPANE I 123; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

ALZHEIMER DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; RADIODIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LEWY BODY DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TROPANES;

EID: 84857439621     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.09.015     Document Type: Review

References (31)

1. Walker R.W., Walker Z. Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 2009, 24(Suppl. 2):S754-S759.
2. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., et al. Dementia with Lewy bodies. Lancet Neurol 2004, 3(1):19-28.
3. Lopez O.L., Becker J.T., Kaufer D.I., Hamilton R.L., Sweet R.A., Klunk W., et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002, 59(1):43-46.
4. Merdes A.R., Hansen L.A., Jeste D.V., Galasko D., Hofstetter C.R., Ho G.J., et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003, 60(10):1586-1590.
5. Aarsland D., Perry R., Larsen J.P., McKeith I.G., O'Brien J.T., Perry E.K., et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005, 66(5):633-637.
6. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356(9247):2031-2036.
7. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999, 122(Pt 8):1449-1468.
8. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65(12):1863-1872.
9. National Institute for Health and Clinical Excellence (NICE) Dementia: quick reference guide CG42 2011, National Institute for Health and Clinical Excellence, London.
10. Glas A.S., Lijmer J.G., Prins M.H., Bonsel G.J., Bossuyt P.M. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56(11):1129-1135.
11. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
12. Reitsma J.B., Glas A.S., Rutjes A.W., Scholten R.J., Bossuyt P.M., Zwinderman A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005, 58(10):982-990.
13. Rutter C.M., Gatsonis C.A. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001, 20(19):2865-2884.
14. O'Brien J.T., McKeith I.G., Walker Z., Tatsch K., Booij J., Darcourt J., et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009, 194(1):34-39.
15. Yamamoto R., Iseki E., Marui W., Togo T., Katsuse O., Kato M., et al. Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 2005, 25(3):188-194.
16. Zaccai J., Brayne C., McKeith I., Matthews F., Ince P.G. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology 2008, 70(13):1042-1048.
17. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351(24):2498-2508.
18. Marshall V.L., Reininger C.B., Marquardt M., Patterson J., Hadley D.M., Oertel W.H., et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009, 24(4):500-508.
19. Vlaar A.M., van Kroonenburgh M.J., Kessels A.G., Weber W.E. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007, 7:27.
20. McKeith I., O'Brien J., Walker Z., Tatsch K., Booij J., Darcourt J., et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6(4):305-313.
21. Kemp P.M., Clyde K., Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. Nucl Med Commun 2011, 32(4):298-302.
22. Barber R., Gholkar A., Scheltens P., Ballard C., McKeith I.G., O'Brien J.T. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999, 52(6):1153-1158.
23. Cousins D.A., Burton E.J., Burn D., Gholkar A., McKeith I.G., O'Brien J.T. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003, 61(9):1191-1195.
24. Kemp P.M., Hoffmann S.A., Tossici-Bolt L., Fleming J.S., Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun 2007, 28(6):451-456.
25. Kemp P.M., Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007, 28(7):511-519.
26. Colloby S.J., Firbank M.J., Pakrasi S., Lloyd J.J., Driver I., McKeith I.G., et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatr 2008, 20(6):1124-1140.
27. Sinha N., Firbank M., O'Brien J.T. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry published online 1 Jul 2011, 10.1002/gps.2749.
28. Hu X.S., Okamura N., Arai H., Higuchi M., Matsui T., Tashiro M., et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000, 55(10):1575-1577.
29. Koeppe R.A., Gilman S., Junck L., Wernette K., Frey K.A. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 2008, 4(Suppl. 1):S67-S76.
30. Treglia G., Cason E. Diagnostic performance of Myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging published online 17 Nov 2010, 10.1111/j.1552-6569.2010.00532.x.
31. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61(6):919-925.